Genelux (GNLX) Asset Utilization Ratio (2023 - 2024)
Genelux (GNLX) posted Asset Utilization Ratio of 0.0 for Q4 2024, up 13.95% on a QoQ basis from 0.0 in Q3 2024, and down 96.11% year-over-year from 0.01 in Q1 2024.
Powered by 
Analysis
Genelux (GNLX) Asset Utilization Ratio (2023 - 2024) Analysis & Trends
Genelux has reported Asset Utilization Ratio for 2 years, with the latest figure at 0.0 in Q4 2024.
- On a quarterly basis, Asset Utilization Ratio fell 96.11% year-over-year to 0.0 in Q4 2024; TTM through Dec 2024 was 0.0, a 96.11% decrease from a year earlier, with the FY2025 full-year figure at 0.0, up 16.5% from the prior year.
- Asset Utilization Ratio was 0.0 for Q4 2024 at Genelux, up from 0.0 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.01 in Q4 2023, with the low at 0.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 0.38 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 0.20 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.33 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 0.00 |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 0.00 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.01 |